- Home
- RLGT vs TNGX Comparison
RLGT vs TNGX Comparison
Compare RLGT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLGT | TNGX |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.6M | 1.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RLGT | TNGX |
|---|---|---|
| Price | $6.32 | $8.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $8.00 | ★ $12.50 |
| AVG Volume (30 Days) | 163.0K | ★ 2.6M |
| Earning Date | 02-09-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.35 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $925,786,000.00 | $66,501,000.00 |
| Revenue This Year | $3.77 | $52.80 |
| Revenue Next Year | $3.51 | N/A |
| P/E Ratio | $20.42 | ★ N/A |
| Revenue Growth | 16.42 | ★ 53.29 |
| 52 Week Low | $5.44 | $1.03 |
| 52 Week High | $7.94 | $11.20 |
Technical Indicators
Market Signals| Indicator | RLGT | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 44.13 | 49.33 |
| Support Level | $6.31 | $8.45 |
| Resistance Level | $6.55 | $9.00 |
| Average True Range (ATR) | 0.15 | 0.52 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 3.64 | 31.74 |
Price Performance
Historical ComparisonAbout RLGT Radiant Logistics Inc.
Radiant Logistics Inc operates as a third-party logistics company, providing multi-modal transportation and logistics services to customers based in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services and freight brokerage services including truckload services, less-than-truckload (LTL) services, and intermodal services. It has two geographic operating segments: the United States and Canada. Maximum revenue is generated in the United States.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.